Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Generate Investment Management Ltd

Generate Investment Management Ltd boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 25.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,165 shares of the medical research company’s stock after purchasing an additional 4,866 shares during the period. Generate Investment Management Ltd’s holdings in Thermo Fisher Scientific were worth $14,948,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $295,000. RFG Advisory LLC increased its stake in Thermo Fisher Scientific by 11.0% during the 1st quarter. RFG Advisory LLC now owns 3,697 shares of the medical research company’s stock worth $2,149,000 after buying an additional 365 shares during the period. Congress Asset Management Co. MA lifted its holdings in Thermo Fisher Scientific by 5.7% in the 1st quarter. Congress Asset Management Co. MA now owns 21,250 shares of the medical research company’s stock worth $12,351,000 after buying an additional 1,155 shares in the last quarter. Mountain Pacific Investment Advisers Inc. ID boosted its position in Thermo Fisher Scientific by 1.1% in the 1st quarter. Mountain Pacific Investment Advisers Inc. ID now owns 42,122 shares of the medical research company’s stock valued at $24,482,000 after buying an additional 451 shares during the last quarter. Finally, International Assets Investment Management LLC increased its position in shares of Thermo Fisher Scientific by 3.3% during the first quarter. International Assets Investment Management LLC now owns 1,964 shares of the medical research company’s stock worth $1,134,000 after acquiring an additional 62 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on TMO shares. JPMorgan Chase & Co. increased their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Stifel Nicolaus raised their price target on shares of Thermo Fisher Scientific from $615.00 to $680.00 and gave the stock a “buy” rating in a research report on Friday, September 20th. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Morgan Stanley raised their price objective on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Finally, Evercore ISI increased their price target on shares of Thermo Fisher Scientific from $605.00 to $630.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $656.16.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the transaction, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,084 shares of company stock valued at $14,094,292. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Up 0.4 %

TMO stock opened at $601.71 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The firm’s 50-day simple moving average is $607.99 and its 200 day simple moving average is $584.09. The stock has a market cap of $229.85 billion, a PE ratio of 37.33, a price-to-earnings-growth ratio of 3.86 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. During the same quarter in the previous year, the company posted $5.15 earnings per share. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.